Literature DB >> 22231382

Heterozygosity for an in-frame deletion causes glutaryl-CoA dehydrogenase deficiency in a patient detected by newborn screening: investigation of the effect of the mutant allele.

Peter Bross1, Jane B Frederiksen, Anne S Bie, Jakob Hansen, Johan Palmfeldt, Marit N Nielsen, Morten Duno, Allan M Lund, Ernst Christensen.   

Abstract

A patient with suspected glutaric aciduria type 1 (GA-1) was detected by newborn screening. GA-1 is known as an autosomal recessively inherited disease due to defects in the gene coding for glutaryl-CoA dehydrogenase (GCDH), a mitochondrial enzyme involved in the catabolism of the amino acids hydroxylysine, lysine and tryptophan. DNA and cDNA sequencing revealed a 18 bp deletion (c.553_570del18) resulting in deletion of six amino acids (p.Gly185_Ser190del) in one allele and no sequence changes in the other allele. Confirmatory biochemical analysis of blood, urine and cultured fibroblasts from the proband were consistent with a mild biochemical GA-1 phenotype. Recombinant expression of the mutant variant in E. coli showed that the GCDH-(p.Gly185_Ser190del) protein displayed severely decreased assembly into tetramers and enzyme activity. To discover a potential dominant negative effect of the mutant protein, we engineered a prokaryotic expression system in which expression of a wild type and a mutant GCDH allele is controlled by separately inducible promoters. These cells displayed decreased levels of GCDH tetramer and enzyme activity when expressing both the wild type and the mutant GCDH variant protein compared to the situation when only the wild type allele was expressed. Further experiments suggest that the major impact of the GCDH-(p.Gly185_Ser190del) protein in heterozygous cells consists of hampering the assembly of wild type GCDH into tetramers. Our experimental data are consistent with the hypothesis that heterozygosity for this mutation confers a dominant negative effect resulting in a GCDH enzyme activity that is significantly lower than the expected 50%.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231382     DOI: 10.1007/s10545-011-9437-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  Acyl-CoA dehydrogenases: Dynamic history of protein family evolution.

Authors:  Zuzana Swigonová; Al-Walid Mohsen; Jerry Vockley
Journal:  J Mol Evol       Date:  2009-07-29       Impact factor: 2.395

2.  Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency.

Authors:  E Christensen; A Ribes; B Merinero; J Zschocke
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 3.  Protein misfolding and degradation in genetic diseases.

Authors:  P Bross; T J Corydon; B S Andresen; M M Jørgensen; L Bolund; N Gregersen
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

4.  Co-overexpression of bacterial GroESL chaperonins partly overcomes non-productive folding and tetramer assembly of E. coli-expressed human medium-chain acyl-CoA dehydrogenase (MCAD) carrying the prevalent disease-causing K304E mutation.

Authors:  P Bross; B S Andresen; V Winter; F Kräutle; T G Jensen; A Nandy; S Kølvraa; S Ghisla; L Bolund; N Gregersen
Journal:  Biochim Biophys Acta       Date:  1993-10-20

Review 5.  Myotonia congenita.

Authors:  Christoph Lossin; Alfred L George
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

6.  Crystal structures of human glutaryl-CoA dehydrogenase with and without an alternate substrate: structural bases of dehydrogenation and decarboxylation reactions.

Authors:  Zhuji Fu; Ming Wang; Rosemary Paschke; K Sudhindra Rao; Frank E Frerman; Jung-Ja P Kim
Journal:  Biochemistry       Date:  2004-08-03       Impact factor: 3.162

7.  Type I glutaric aciduria, part 1: natural history of 77 patients.

Authors:  Kevin A Strauss; Erik G Puffenberger; Donna L Robinson; D Holmes Morton
Journal:  Am J Med Genet C Semin Med Genet       Date:  2003-08-15       Impact factor: 3.908

8.  The Hsp60-(p.V98I) mutation associated with hereditary spastic paraplegia SPG13 compromises chaperonin function both in vitro and in vivo.

Authors:  Peter Bross; Søren Naundrup; Jakob Hansen; Marit Nyholm Nielsen; Jane Hvarregaard Christensen; Mogens Kruhøffer; Johan Palmfeldt; Thomas Juhl Corydon; Niels Gregersen; Debbie Ang; Costa Georgopoulos; Kåre Lehmann Nielsen
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

9.  Isoalloxazine ring of FAD is required for the formation of the core in the Hsp60-assisted folding of medium chain acyl-CoA dehydrogenase subunit into the assembly competent conformation in mitochondria.

Authors:  T Saijo; K Tanaka
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

Review 10.  Diagnosis and management of glutaric aciduria type I--revised recommendations.

Authors:  Stefan Kölker; Ernst Christensen; James V Leonard; Cheryl R Greenberg; Avihu Boneh; Alberto B Burlina; Alessandro P Burlina; Marjorie Dixon; Marinus Duran; Angels García Cazorla; Stephen I Goodman; David M Koeller; Mårten Kyllerman; Chris Mühlhausen; Edith Müller; Jürgen G Okun; Bridget Wilcken; Georg F Hoffmann; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2011-03-23       Impact factor: 4.982

View more
  2 in total

Review 1.  Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision.

Authors:  Nikolas Boy; Chris Mühlhausen; Esther M Maier; Jana Heringer; Birgit Assmann; Peter Burgard; Marjorie Dixon; Sandra Fleissner; Cheryl R Greenberg; Inga Harting; Georg F Hoffmann; Daniela Karall; David M Koeller; Michael B Krawinkel; Jürgen G Okun; Thomas Opladen; Roland Posset; Katja Sahm; Johannes Zschocke; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-11-16       Impact factor: 4.982

Review 2.  Mitochondrial proteomics--a tool for the study of metabolic disorders.

Authors:  Niels Gregersen; Jakob Hansen; Johan Palmfeldt
Journal:  J Inherit Metab Dis       Date:  2012-04-17       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.